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Cutaneous spindle cell malignancy is associated with a broad differential diagnosis, particularly in the absence of a known primary
melanocytic lesion. We present an unusually challenging patient who presented with clinical symptoms involving cranial nerves
VII and VIII and a parotid-region mass, which was S100-positive while lacking in melanocytic pigment and markers. Over a year
after resection of the parotid mass, both a cutaneous primary lentigomaligna melanoma and ametastatic CP angle melanoma were
diagnosed in the same patient, prompting reconsideration of the diagnosis in the original parotid-region mass. Next-generation
sequencing of a panel of cancer-associated genes demonstrated 19 identical, clinically significant mutations as well as a high tumor
mutation burden in both the parotid-region and CP angle tumors, indicating a metastatic relationship between the two and a
melanocytic identity of the parotid-region tumor.
1. Introduction
Melanoma is heterogeneous in both clinical behavior and his-
tomorphological appearance andmay resemble other types of
tumors, particularly in the case of a spindle cell malignancy
[1–4]. Desmoplastic melanoma often lacks melanin pigment
and is positive for S100 by immunohistochemistry but nega-
tive for other markers of melanocytic differentiation.
Malignant peripheral nerve sheath tumor (MPNST) is
a spindle cell neoplasm which may appear morphologically
similar to spindle cell and desmoplasticmelanoma. Like these
subtypes of melanoma, MPNST may show patchy S100 posi-
tivity in the absence of melanocytic markers. The differential
diagnosis of an S100-positive spindle cell lesion in a cutaneous
location is challenging given these overlapping features [1, 2,
4].
Lentigo maligna melanoma (LMM) arises in the sun-
damaged skin of older adults; early clinical identification of
LMM on the face can be difficult due to the presence of
multiple solar lentigines [5].
We present a case for which next-generation sequencing
of a panel of cancer-associated genes established a relation-
ship between an intracranial melanoma and a prior right
parotid region tumor. Further, the assay identified FDA-
approved therapies targeted for specific genetic alterations in
this patient.We suggest that genomic analysis may serve both
diagnostic and predictive functions in similar, challenging
cases.
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Figure 1: CT (a) and PET (b) images of the FDG-avid mass, centered along the anterior aspect of the right masseter muscle, not involving
parotid.
2. Case Presentation
A 63-year-old female sought medical intervention for a
painless, firm, mobile mass within her right cheek. For the
previous year-and-a-half, she had experienced right facial
nerve paralysis, which progressed to facial numbness and
progressive hearing loss. A PET-CT scan showed an FDG-
avid 2.2 x 2.0 cmmass centered along the anterolateral aspect
of the right masseter muscle without parotid gland involve-
ment (Figure 1). AnMRI of the lesion indicated enhancement
of the right trigeminal nerve from its origin to the point
where it entered Meckel’s cave along with enhancement of
the right facial nerve from the internal auditory canal to
the middle ear. A fine needle aspiration of the mass showed
clusters of atypical spindled cells with elongated, irregular
nuclei; the tumor was diagnosed as a malignancy consistent
with neural ormesenchymal origin (Figures 2(a) and 2(b)). A
total right parotidectomy with selective resection of the facial
and trigeminal (mandibular division) nerves was performed.
Histopathologic review showed a tumor adjacent to, but
not primarily involving, the parotid gland, characterized by
a proliferation of spindle cells, many with multiple nuclei,
grouped in interwoven fascicles and heavily interwoven
with lymphocytes (Figure 2(c)). Nuclei were prominent and
markedly pleomorphic, and the mitotic index was high
(28/10 high-power fields; Figure 2(d)). Immunohistochemi-
cal stains showed S100 to be strongly and diffusely positive
(Figure 2(e)); collagen IV was 2+ positive around individual
tumor cells (Figure 2(f)); Mart1/MelanA and HMB-45 were
negative (not shown). Pancytokeratin, CK5/6, p63, desmin,
CD34, and the mutant protein BRAF V600E also were
negative. The tumor was diagnosed as a poorly differentiated
MPNST. There was no evidence of metastatic tumor in
the additionally submitted lymph nodes. The patient subse-
quently completed radiation therapy.
Approximately eightmonths after the initial resection, the
patient presented with severe hearing loss in her right ear and
difficulty with walking and balance. An MRI revealed a 6.4
mm, contrast-enhancing lesion at the right cerebellopontine
(CP) angle (Figure 3) and a similar 3.8 mm lesion slightly
distal running along the 7th cranial nerve. At this time, a 1.5
x 1.5 cm irregular pigmented lesion also was noted on her
right cheek. A punch biopsy of this lesion revealed LMM
(Figure 4). In this biopsy, the Breslow depth was 0.25 mm;
neither ulceration nor dermal mitotic activity was noted.
Additionally, although neither lymphovascular nor perineu-
ral invasion was identified, the possibility was raised that
the original parotid-region mass represented a metastatic
melanoma instead of a separate primary MPNST.
The patient then underwent resection of the CP angle
tumor as well as cranial nerve 7 approximately 23 months
after the parotid-region mass was resected. Histopathologic
review demonstrated spindled-to-epithelioid cells with pleo-
morphic nuclei (Figure 5(a)). In several areas, fine, golden-
brown pigment was observed. The mitotic index was 4/10
high-power fields, and a Ki-67 immunostain showed an 18%
index of proliferation. Similar to the original parotid-region
mass, the tumor showed strong and diffuse positivity for
S100 (Figure 5(b)), and there was weak focal reactivity for
collagen IV (Figure 5(c)). Unlike the originally resected
parotid-regionmass, the CP angle lesion exhibited strong and
diffuse positivity for Mart1/MelanA and HMB-45 (Figures
5(d) and 5(e)) and was diagnosed as malignant melanoma.
She also underwent a wide excision of her right cheek
melanoma, which revealed residual melanoma with a Bres-
low depth of 0.55 mm. Again, no dermal mitotic activity,




Figure 2: (a), (b) Pap-stained cytologic preparations of the right parotid-region mass; (c), (d) hematoxylin and eosin-stained sections of the
parotid-region mass; immunostains for S100 (e); collagen IV (f).
ulceration, lymphovascular, or perineural invasion were
noted. The tumor was again positive for Mart1/MelanA, as
was demonstrated in the original biopsy.
Given the uncertain relationship between the original
parotid-region and the CP angle masses, next-generation
sequencing of a panel of 300+ genes was performed on both
the parotid-regionmass and the CP angle lesion (Foundation
Medicine; Boston, MA). Both tumors showed high tumor
mutation burden (TMB), and each showed over twenty
potentially clinically significant genomic alterations; among
these, they shared nineteen (Table 1).
3. Discussion
This case highlights several important clinical and diagnostic
challenges in a complex patient. Our patient presented with
facial paralysis and numbness, prompting imaging studies
which revealed a spindle cell mass in the parotid-region
with morphological and immunohistochemical features con-
sistent with an MPNST for which she underwent resection
as well as radiation therapy. At that time, the patient had
no known melanocytic lesions. Months later, a pigmented
lesion on her right cheek was clinically recognized, biopsied,
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Table 1: Genomic alterations in the parotid-region and CP angle tumors.
Parotid-region tumor CP angle tumor
NF1 R2517∗ NF1 R2517∗
MTOR E1799K MTOR E1799K
CDKN2A p16INK4a P81L CDKN2A p16INK4a P81L
EPHA3 D832N EPHA3 D832N
ERBB4 E563K ERBB4 E563K
FANCA R1084C FANCA Q869∗, R1084C
FLT1 E72K FLT1 E72K
GNAS P201L GNAS P201L
IKZF1 splice site 851-1G>A IKZF1 splice site 851-1G>A
LRP1B H2277Y, S1992F, splice site 13325-1G>A LRP1B H2277Y, Q763∗, S1992F, splice site 13325-1G>A
MAGI2 E1166K MAGI2 E1166K
NOTCH2 Q2325∗ NOTCH2 Q2325∗
PIK3CG D192N PIK3CG D192N
SNCAIP E661K SNCAIP E661K
SPTA1 R1281C, R1659∗ SPTA1 Q1720∗, R1281C, R1659∗
TP53 S241F TP53 S241F
Tumor mutation burden TMB-High; 186 muts/Mb Tumor mutation burden TMB-High; 225 muts/Mb
FAM123B C635∗ ATM R3047∗
EGFR amplification SLIT2 R617∗
TERT promoter -124C>T
Italic: identical mutations in parotid/CP angle.
Bold: unique to parotid.
Underline: unique to CP angle.
Figure 3: T1-weighted image with contrast, highlighting new right-
sided cerebellopontine angle lesion (arrow).
and diagnosed as LMM. Imaging also identified a small (<1
cm) CP angle lesion that was resected and diagnosed as
melanoma.
One obvious possibility was that the right cheek LMM
represented the primary tumor, and the right parotid lesion
as well as the CP angle tumor represented metastatic
sites. Although lentigo maligna melanoma is sometimes
considered more “benign” on the spectrum of melanoma
subtypes, it is often associated with lymphovascular spread
and metastasis. One recent study examined the risk factors
associated with subclinical spread of invasive melanoma [6];
multivariate analysis identified tumor localization on the
head and neck and history of previous treatment, both of
which are relevant features in this patient, as well as age >
65 years and mitotic activity > 1/mm2. Tumor histologic type
and Breslow depth, interestingly, were not risk factors for
subclinical spread of invasive melanoma.
Since the right parotid lesion demonstrated a unique
morphologic appearance and immunohistochemical pro-
file (negative for both Mart1/MelanA and HMB-45), the
question as to how these three lesions were possibly
related prompted additional diagnostic studies, namely, next-
generation sequencing using a broad, cancer-associated
panel. Of the three tumor sites, the parotid-region and the CP
angle tumors contained adequate cellularity required to per-
form the assay and were both shown to not only demonstrate
the high tumormutation burden characteristic ofmelanomas
on chronic sun-exposed skin [7] but also share at least
nineteen clinically significant alterations. Importantly, these
alterations include a truncating mutation in NF1 (R2517∗).
These data strongly suggest that the parotid-region and CP
angle tumors are genetically related given the vanishingly
small probability that nineteen identical alterations arose by
chance.
This patient’s tumors thusmight be classified as belonging
to the “NF1” subtype in the proposed genomic classification
of cutaneous melanoma from the Cancer Genome Atlas
project [8]. As compared with other subtypes, NF1 subtype
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Figure 4: Hematoxylin and eosin-stained section (a) and MART1/Melan A immunostain (b) demonstrating lentigo maligna melanoma of
the right cheek (400X power).
(a) (b) (c)
(d) (e)
Figure 5: (a) Hematoxylin and eosin-stained section of CP angle tumor; immunostains for S100 (b), collagen IV (c), Mart1/Melan A (d), and
HMB-45 (e).
melanomas show higher tumor mutation burdens and the
strongest UV mutation signature [9]. Mutations in NF1
are more common in melanomas occurring on chronically
sun-exposed skin or in older patients [10, 11], melanomas
with higher mutation burden [11] or wild-type for BRAF
and NRAS [10, 12, 13], and the clinicopathologic subtype,
desmoplastic melanoma [14–16]. Interestingly, a mechanistic
link has been proposed betweenNF1 loss and anMPNST-like
melanoma phenotype [17].
Three of the nineteen shared genomic alterations, includ-
ing high TMB; NF1 R2517∗; and MTOR E1799K, are asso-
ciated with FDA-approved therapies and with investigative
therapies in clinical trials. Although to date the patient has
required no further oncologic treatment, a priori knowledge
of specific genomic alterations in these tumors provides
options should additional therapy be indicated.
Another interesting aspect of this case is the unusual
presentation of malignant melanoma in the CP angle. The
MRI showing spread of melanoma along the 7th and 8th
cranial nerves suggests that the melanoma reached the CP
angle via the leptomeninges. Though malignant melanoma
has a high propensity to metastasize to the brain, it is
usually by hematogenous spread [2]. Additionally, malignant
melanoma to the CP angle is rare, accounting for only
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0.2-0.7% of neoplasms in this location [18]. In fact, Gerganov
et al. report that, at the time of their writing, there were
only seventeen cases of intracranial metastasis of malignant
melanoma to the CP angle reported in literature [19].
In conclusion, this patient had an unusual presentation of
malignantmelanoma.The use of next-generation sequencing
was valuable to clarify the relationship between the parotid-
region mass and the CP angle lesion. This case highlights the
potential use of next-generation sequencing in the diagnosis
of traditionally difficult-to-assess tumors.
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